Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.

Abstract

OBJECTIVES Severe asthma comprises several distinct phenotypes. Consequently, patients with severe asthma can be eligible for more than one biologic treatment targeting Th2 inflammation, such as anti-interleukin (IL)-5 and anti-immunoglobulin (Ig) E. The objective of this study was to describe treatment eligibility and overlap in treatment eligibility for… (More)
DOI: 10.1080/02770903.2017.1322611

Topics

Cite this paper

@article{Albers2017BiologicTE, title={Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.}, author={Frank Albers and Hanna M{\"{u}llerova and Necdet B Gunsoy and Ji-Yeon Shin and Linda M Nelsen and Eric S Bradford and Sarah M Cockle and Robert Y. Suruki}, journal={The Journal of asthma : official journal of the Association for the Care of Asthma}, year={2017}, pages={1-9} }